Table 5.
Cost differences between chemotherapy-based and hormone therapy-based therapy options based on hormone therapy sensitivitya
| Total Cohort Analysis | Subgroup analysis | |||
|---|---|---|---|---|
| Patient group description | All patients (n = 355) | HT-refractoryb in 1st line (n = 107) | HT-eligiblec in 2nd line (n = 248) | |
| Total cost difference (over 3 lines of therapy)d | HT instead of CTx in 1st line | €14 362 | €7300 | NA |
| HT instead of CTx in 2nd line | €10 368 | NA | €10 300 | |
| Cost difference (for 1 line of therapy)d | 1st line HT vs 2nd line CTx | €9879 (~€1900/mo) | €7550 (~€1650/mo) | NA |
| 1st line HT vs 1st line CTx | €15 167 (~€2500/mo) | €13 850 (~€2350/mo) | NA | |
| 2nd line HT vs 2nd line CTx | €8201 (~€1700/mo) | NA | €8550 (~€1700/mo) | |
Abbreviations: ABC advanced breast cancer, CTx chemotherapy, HT hormone therapy, mo month, NA not applicable
aNumbers in the table reflect cost savings with HT versus CTx
bHormone refractory indicated recurrence within 1 year of adjuvant HT
cHormone eligible indicates de novo (no adjuvant therapy) or recurrent disease ≥1 year following adjuvant HT
dCosts analysis was based on unit cost assumptions for each country, which were then averaged